Barclays’s Argos Therapeutics, Inc. ARGS Stock Holding History

Barclays’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1	Closed	–	–	7661
2018 Q1	$0	Buy	+1	New	+$2	﹤0.01%	7664
2017 Q4	–	Sell	-5	Closed	–	–	7393
2017 Q3	$0	Sell	5 -328	-98%	-$1.57K	﹤0.01%	7338
2017 Q2	$2K	Buy	333 +295	+776%	+$2.51K	﹤0.01%	6481
2017 Q1	$0	Buy	38 +20	+111%	+$1.27K	﹤0.01%	7279
2016 Q4	$2K	Buy	18 +9	+100%	+$842	﹤0.01%	6433
2016 Q3	$1K	Sell	9 -156	-95%	-$16.3K	﹤0.01%	6566
2016 Q2	$20K	Buy	+165	New	+$22K	﹤0.01%	5281
2014 Q4	–	Sell	-3	Closed	-$1K	–	8039
2014 Q3	$1K	Sell	3 -299	-99%	-$46.7K	﹤0.01%	7625
2014 Q2	$48K	Buy	302 +296	+4,933%	+$48.9K	﹤0.01%	5983
2014 Q1	$1K	Buy	+6	New	+$1.2K	﹤0.01%	7539

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Barclays's ARGS Position: Q2 2018 in Review

Barclays sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 1 share.

Barclays first reported a position in ARGS in Q1 2014 and held it in 10 quarters. The position peaked at $48K in Q2 2014. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

Barclays reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Barclays sold 1 Argos Therapeutics, Inc. share in Q2 2018.
Barclays first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
Barclays's Argos Therapeutics, Inc. position peaked at $48K in Q2 2014.
4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.